A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
NCT ID: NCT03517488
Last Updated: 2022-12-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
150 participants
INTERVENTIONAL
2018-07-10
2022-09-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03170960
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
NCT06276491
A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
NCT06873789
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
NCT07123103
Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies
NCT02030067
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
XmAb20717
XmAb20717 administered by intravenous dosing on Days 1 and 15 of each 28-day cycle for a total of two cycles
XmAb20717
Monoclonal bispecific antibody
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
XmAb20717
Monoclonal bispecific antibody
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
PART A (Dose Escalation Cohorts)
1. Melanoma;
2. Breast carcinoma that is estrogen receptor, progesterone receptor, and Her2 negative (triple-negative breast cancer; TNBC);
3. Hepatocellular carcinoma;
4. Urothelial carcinoma;
5. Squamous cell carcinoma of the head and neck;
6. Renal cell carcinoma (clear cell predominant type);
7. Microsatellite instability-high or mismatch repair deficient colorectal carcinoma or endometrial carcinoma;
8. Non-small cell lung carcinoma;
9. Gastric or gastroesophageal junction adenocarcinoma
10. Mesothelioma;
11. High-grade neuroendocrine carcinoma, including small cell carcinoma of the lung
12. Cervical cancer;
13. Squamous cell carcinoma of the anus
PART B (Dose Expansion Cohorts):
1. Melanoma
2. Renal cell carcinoma (clear cell predominant type)
3. Non-small cell lung carcinoma
4. Castrate-resistant adenocarcinoma of the prostate, defined as progressive disease after surgical castration, or progression in the setting of medical androgen ablation with a castrate level of testosterone (\< 50 ng/dL)
5. Nasopharyngeal carcinoma
6. Cholangiocarcinoma
7. Basal cell carcinoma
8. Squamous cell carcinoma of the anus
9. Mesothelioma
10. Ovarian or fallopian tube carcinoma
11. Malignant adnexal neoplasms (including, but not limited to, sebaceous carcinoma, trichilemmal carcinoma, pilomatrix carcinoma, eccrine carcinoma, hidradenocarcinoma, adnexal carcinoma with divergent differentiation, papillary digital eccrine adenocarcinoma, microcystic adnexal carcinoma, and clear cell eccrine carcinoma)
12. Thymoma
13. Thymic carcinoma
14. Squamous cell carcinoma of the penis
15. Neuroendocrine carcinoma
16. Vulvar cancer
17. Non-squamous cell salivary gland carcinoma (except adenoid cystic carcinoma)
18. Subjects with other solid tumors for which there is published evidence of anti-tumor activity with anti-PD1/PDL1 and/or anti-CTLA4-directed therapy but for which there is no FDA-approved anti-PD1/PDL1 or CTLA4-directed checkpoint inhibitor treatment may be eligible for Part B after approval by the Medical Monitor.
* All subjects' cancer must have progressed after treatment with all standard therapies or have no appropriate available therapies.
* Subjects, except those with adenocarcinoma of the prostate, must have measurable disease by RECIST 1.1.
* Have available adequate archival formalin-fixed paraffin-embedded block(s)/slides containing tumor or adequate pre-dose fresh tumor biopsy tissue
* ECOG performance status of 0 - 1
* Subjects with adenocarcinoma of the prostate must have evaluable disease (measurable or nonmeasurable lesions) by PCWG3.
Exclusion Criteria
* Treatment with any CTLA4 antibody within 6 weeks of the start of study drug.
* Treatment with nivolumab or any PDL1 or PDL2-directed antibody within 4 weeks of the start of study drug.
* Treatment with pembrolizumab within 4 - 12 weeks of the start of study drug (cohort dependent).
* Treatment with any other anticancer therapy within 2 weeks of the start of study drug (i.e., other immunotherapy, chemotherapy, radiation therapy, etc.). Subjects with prostate cancer may continue LHRH analogue therapy.
* A life-threatening (Grade 4) immune-mediated AE related to prior immunotherapy.
* Failure to recover from any immune-related toxicity from prior cancer therapy to ≤ Grade 1, except if previous immune-related endocrinopathy is medically managed with hormone replacement therapy only.
* Failure to recover from any other toxicity (other than immune-related toxicity) related to previous anticancer treatment to ≤ Grade 2.
* Have known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, ie, are without evidence of progression for at least 4 weeks by repeat imaging, are clinically stable, and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
* Active known or suspected autoimmune disease (except that subjects are permitted to enroll if they have vitiligo; type 1 diabetes mellitus or residual hypothyroidism due to an autoimmune condition that is treatable with hormone replacement therapy only; psoriasis, atopic dermatitis, or another autoimmune skin condition that is managed without systemic therapy; or arthritis that is managed without systemic therapy beyond oral acetaminophen and non-steroidal anti-inflammatory drugs).
* Has any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within 14 days prior to first dose of study drug (except that inhaled or topical corticosteroids or brief courses of corticosteroids given for prophylaxis of contrast dye allergic response are permitted).
* Receipt of an organ allograft.
* Prior treatment with any checkpoint inhibitor therapy regimen that targets both PD1/L1 and CTLA-4.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ICON plc
INDUSTRY
Xencor, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zequn Tang, MD
Role: STUDY_DIRECTOR
Xencor, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
Los Angeles, California, United States
UCLA Hematology-Oncology Clinic (Westwood)
Los Angeles, California, United States
University of California San Diego Moores Cancer Center
San Diego, California, United States
University of California San Francisco Medical Center
San Francisco, California, United States
Emory University
Atlanta, Georgia, United States
University of Chicago Medicine
Chicago, Illinois, United States
The University of Kansas Clinical Research Center
Fairway, Kansas, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, United States
Columbia University Medical Center - Herbert Irving Pavilion
New York, New York, United States
Providence Portland Medical Center
Portland, Oregon, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah, United States
Emily Couric Clinical Cancer Center
Charlottesville, Virginia, United States
Seattle Cancer Care Alliance
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DUET-2
Identifier Type: OTHER
Identifier Source: secondary_id
XmAb20717-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.